Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [919]
News [2671]
Articles [120]
Editorials [3]
Conferences [85]
elearning [27]
WCLC 2025: Ivonescimab plus chemotherapy improves progression-free survival in patients with EGFR+ NSCLC following 3rd-generation EGFR-TKI therapy
WCLC 2025: Ivonescimab plus chemotherapy improves progression-free survival in patients with EGFR+ NSCLC following...
WCLC 2025: Zidesamtinib shows durable responses in ROS1 TKI pre-treated NSCLC, including patients with CNS disease and ROS1 G2032R mutations
WCLC 2025: Zidesamtinib shows durable responses in ROS1 TKI pre-treated NSCLC, including patients with CNS disease...
WCLC 2025: Nivolumab maintains quality of life and reduces symptom deterioration in resectable NSCLC
WCLC 2025: Nivolumab maintains quality of life and reduces symptom deterioration in resectable NSCLC
WCLC 2025: Continuing osimertinib treatment through progression with the addition of chemo improves progression-free survival in EGFR-mutated NSCLC
WCLC 2025: Continuing osimertinib treatment through progression with the addition of chemo improves progression...
WCLC 2025: New antibody-drug conjugate shows promising efficacy in EGFR-mutated NSCLC patients
WCLC 2025: New antibody-drug conjugate shows promising efficacy in EGFR-mutated NSCLC patients
WCLC 2025: Iza-Bren in combination with osimertinib shows 100% response rate in EGFR-mutated NSCLC, phase II study finds
WCLC 2025: Iza-Bren in combination with osimertinib shows 100% response rate in EGFR-mutated NSCLC, phase II study...
Two studies reveal new variant of mesothelioma
Two studies reveal new variant of mesothelioma
Boosting cancer treatment: enhanced effectiveness of At-211-labeled agent achieved through combination with immunotherapy
Boosting cancer treatment: enhanced effectiveness of At-211-labeled agent achieved through combination with...
FDA grants accelerated approval to zongertinib for non-squamous NSCLC with HER2 TKD activating mutations
FDA grants accelerated approval to zongertinib for non-squamous NSCLC with HER2 TKD activating mutations
New strategy to boost the effect of immunotherapy in the most aggressive form of lung cancer
New strategy to boost the effect of immunotherapy in the most aggressive form of lung cancer

More from ecancer

Register with ecancer to receive our newsletter

Register here

Explore patient resources at ecancerpatient

Visit site

Find out more about ecancer and the work we do

About ecancer

Support ecancer's work by making a donation